Consolidated Edison, Inc. vs Invesco Ltd. — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while Invesco Ltd. trades at $30.09 (market cap $13.28B). The key difference: Consolidated Edison, Inc. is far larger — about 3× Invesco Ltd.'s market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Invesco Ltd. for 77 Days on average.
| ED | IVZ | |
|---|---|---|
Market Cap | $39.20B | $13.28B |
Volume | 2,142,900 | 3,698,033 |
Sector | Utilities | Financials |
52-Week High | $115.46 | $33.31 |
52-Week Low | $95.37 | $22.44 |
Typical Hold Time | 75 Days | 77 Days |
Enterprise Value | $66.05B | $23.45B |
Dividend Yield | 3.31% | 2.86% |
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $16.92B and net income of $2.02B for 2025, with a net margin of 11.95%. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. The stock is supported by a strong dividend history, with a recent $0.89 dividend declared for H2 2026, and positive news highlighting its economic impact in New York and involvement in electric bus infrastructure.
The outlook for ED is cautiously optimistic, with a consensus price target of $106.33 suggesting modest upside. Strengths include stable cash flow, a solid dividend, and strategic investments in infrastructure. Key risks involve fluctuating earnings, high debt levels, and regulatory pressures. Analyst sentiment is predominantly neutral, with 62.96% hold ratings, indicating a wait-and-see approach amid evolving utility sector dynamics.
Invesco (IVZ) trades at $30.50, showing modest daily gains of 0.39%. The stock presents mixed signals with bearish technical indicators but positive analyst sentiment featuring 12 buy ratings and a $33.71 consensus target. Recent financials show revenue growth to $6.38B in 2025, though net income remains negative at -$281.70M. The company maintains strong operating cash flow of $1.53B and recently announced a $0.22 dividend for H2-2026.
Investment outlook balances analyst optimism against fundamental challenges. The 8.8% upside to consensus target suggests potential, but negative profitability metrics and bearish technicals warrant caution. Key catalysts include Q3 2026 earnings release on October 27 and continued AUM growth momentum, while risks center on margin pressure and market volatility affecting asset management revenues.
Trailing returns across standard periods
Latest headlines on both assets
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →